Navigation Links
Actavis Hails U.S. Supreme Court Decision in Labeling Cases
Date:6/23/2011

MORRISTOWN, N.J., June 23, 2011 /PRNewswire/ -- Actavis applauds the U.S. Supreme Court's decision in the Mensing and Demahy cases as an important step forward for consumer safety and the continued availability of affordable generic medicines.

By a 5-4 majority, the court rejected arguments that generic-drug manufacturers should be subject to state lawsuits alleging "failure to warn" over the contents of their products' labels. Justice Clarence Thomas authored the majority opinion, which concluded that federal law requiring the labels on generic products to be identical to that of their brand counterparts, and prohibiting generic manufacturers from making changes to them, preempted such cases.  

Actavis Inc. CEO Doug Boothe called the decision "an important and necessary step by the Supreme Court to clarify the proper interpretation of the regulations governing pharmaceutical labeling."

"A consistent drug-labeling standard, overseen by the federal Food and Drug Administration, as contemplated by the federal regulations is absolutely essential to protecting the safety and wellbeing of the of American consumers who rely upon generic medications for their health and quality of life," he said. "This ruling furthers meaningful consumer protection while also safeguarding against lawsuits that threaten the availability of safe and affordable pharmaceutical products by misconstruing the labeling responsibilities of generic manufacturers."

The ruling covered three separate cases that were consolidated for argument before the court in March: Actavis v. Mensing, Pliva v. Mensing and Actavis v. Demahy. The key question centered on whether consumers may sue generic drug manufacturers in state court over the contents of product labels that the companies do not control.

Boothe believes a necessary next step is for Congress to take guidance from the decision and address ambiguities in existing laws to confirm the FDA's sole authority to regulate the contents of medication labels.

"The 1980s regulatory structure that governs our industry is incompatible with the realities of the 21st century healthcare marketplace," he said. "Congress must modernize the Food, Drug and Cosmetic Act to reflect these realities, and Actavis welcomes any opportunity to work with members of Congress and the FDA to accomplish this important objective."

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.


'/>"/>
SOURCE Actavis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Alprazolam ODT in the U.S.
2. Actavis Launches Generic Version of Flomax(R) In The U.S.
3. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
4. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
5. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
6. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
7. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
8. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
9. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
10. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
11. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):